According to a recent LinkedIn post from Xeltis, senior clinical and business development leaders are attending the American Society of Diagnostic and Interventional Nephrology 22nd Annual Scientific Meeting in Florida in February 2026. The post notes that Vice Presidents Shawn M. Gage and Luc Verhees will be present, signaling ongoing engagement with key nephrology stakeholders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that Dr. Adrian Sequira of Louisiana State Health Sciences Center is scheduled to present clinical progress updates on aXess, described as Xeltis’ restorative vascular access conduit. This positioning at a specialized scientific forum suggests the company is advancing its dialysis-related technology toward commercialization and seeking clinician feedback.
The post suggests that Xeltis is actively encouraging meeting requests with its team during the event to discuss development progress and commercialization plans. For investors, this visibility and interaction with the interventional nephrology community may be an indicator of continued momentum in clinical trials and potential groundwork for market entry in the vascular access segment.